Eidem Tess M, Coughlan Aisling, Towler Mark R, Dunman Paul M, Wren Anthony William
1University of Rochester Medical Centre, Rochester, NY, USA.
J Biomater Appl. 2014 Apr;28(8):1235-46. doi: 10.1177/0885328213503388. Epub 2013 Sep 12.
Bone cement used in orthopaedic applications can become colonized with bacterial biofilms, resulting in severe medical complications. Consequently, bone cements are often loaded with antibiotics in an effort to prevent bacterial colonization. However, current formulations may not release antibiotics into the environment at sufficient and sustained concentrations required to impede bacterial growth or may be incompatible with antibiotics that are effective against the colonizing organism. Thus, new cement formulation options are needed. This report describes the performance of a novel SiO2-TiO2-ZnO-CaO-SrO-based glass polyalkenoate cement as a carrier of antimicrobials active against Staphylococcus aureus, the predominant cause of orthopaedic biofilm-associated infections. The antibiotic vancomycin and a novel Staphylococcus aureus RnpA inhibitor under pre-clinical development, RNPA1000, were included in these studies. Rheological testing characterized the workability of the glass polyalkenoate cement over a range of powder-to-liquid ratios and polyacrylic acid concentrations and revealed that the most suitable powder-to-liquid ratio was 2/1.25 with 40 wt% polyacrylic acid. Loading glass polyalkenoate cement with either 20-30% RNPA1000 or vancomycin prevented bacterial growth. However, longer incubations allowed for Staphylococcus aureus colonies to form near the vancomycin-infused cement, indicating that vancomycin may not be suitable for long-term biofilm inhibition in comparison to RNPA1000. Scanning electron microscopy and energy-dispersive X-ray analyses confirmed successful incorporation RNPA1000 into the cement matrix and were indicative of its slow release. These studies establish a drug-eluting formulation of glass polyalkenoate cement with great potential in orthopaedic implants that incorporates known antibiotics as well as RNPA1000 to prevent growth of the dangerous pathogen Staphylococcus aureus.
用于骨科的骨水泥可能会被细菌生物膜定植,从而导致严重的医疗并发症。因此,骨水泥通常会添加抗生素以防止细菌定植。然而,目前的配方可能无法以抑制细菌生长所需的足够且持续的浓度将抗生素释放到环境中,或者可能与对定植菌有效的抗生素不相容。因此,需要新的骨水泥配方选择。本报告描述了一种新型的基于SiO2-TiO2-ZnO-CaO-SrO的玻璃聚烯烃酸酯骨水泥作为抗金黄色葡萄球菌抗菌剂载体的性能,金黄色葡萄球菌是骨科生物膜相关感染的主要原因。这些研究中包括了抗生素万古霉素和一种临床前开发的新型金黄色葡萄球菌RnpA抑制剂RNPA1000。流变学测试表征了玻璃聚烯烃酸酯骨水泥在一系列粉液比和聚丙烯酸浓度范围内的可加工性,并表明最合适的粉液比是2/1.25,聚丙烯酸浓度为40 wt%。用20%-30%的RNPA1000或万古霉素加载玻璃聚烯烃酸酯骨水泥可防止细菌生长。然而,较长时间的培养使得金黄色葡萄球菌菌落在注入万古霉素的骨水泥附近形成,这表明与RNPA1000相比,万古霉素可能不适合长期抑制生物膜。扫描电子显微镜和能量色散X射线分析证实RNPA1000成功掺入骨水泥基质,并表明其缓释情况。这些研究建立了一种在骨科植入物中具有巨大潜力的玻璃聚烯烃酸酯骨水泥药物洗脱配方,该配方包含已知抗生素以及RNPA1000,以防止危险病原体金黄色葡萄球菌的生长。